SCHEMBL6907595

SCHEMBL6907595

O=C(CC(=O)Oc1cc(F)c(F)cc1F)Oc1cc(F)c(F)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRA6 Q16445 1/20 0.35
DPP4 P27487 2/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EPHX2 P34913 1/20 0.33
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6907598 0.90 FFAR1 (0.35) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL27769102 0.88 MGAM (0.40) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL27917198 0.87 CYP4F2 (0.41) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL10181392 0.83 ALOX15 (0.45) CYP4F2CYP4A11TAS1R3TAS1R1SMN1; SMN2
SCHEMBL28489058 0.82 CYP4F2 (0.36) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL10180593 0.80 ALOX15 (0.47) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL28106320 0.79 MTNR1A (0.36) CYP4F2CYP4A11GABRA1GABRG2GABRB3
SCHEMBL15763924 0.78 CYP4F2 (0.45) CYP4F2CYP4A11MAPTALDH1A1SMN1; SMN2
SCHEMBL15755542 0.78 TSHR (0.48) MAPTALDH1A1SMN1; SMN2MAPK1KDM4E
SCHEMBL27915961 0.77 KMT2A (0.50) SMN1; SMN2LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9236635-B2 Non-aqueous electrolyte and electricity storage device using same UBE INDUSTRIES, LTD. (JP) 2016-01-12 US disclosed
US-9236635-B2 Non-aqueous electrolyte and electricity storage device using same UBE INDUSTRIES, LTD. (JP) 2016-01-12 US disclosed
US-20140154587-A1 NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD (JP) 2014-06-05 US disclosed
US-20140154587-A1 NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE USING SAME UBE INDUSTRIES, LTD (JP) 2014-06-05 US disclosed
US-20040068141-A1 Process for the synthesis of trifluorophenylacetic acids ARMSTRONG JOSEPH D (US) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068141-A1 Process for the synthesis of trifluorophenylacetic acids PCCA, PAH, PFAS CYP4F2 17/4885CYP4A11 302/4885GABRA1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.